Japanese Phase 1 Study of BMS-844203 (CT322)

Bristol-Myers Squibb (BMS)

Status and phase: Withdrawn; Phase 1

Conditions: Neoplasms

Treatments: Drug: BMS-844203 (CT-322)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01146171

CA196-007

Details and patient eligibility

About

The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group performance 0-1

Exclusion criteria

• Subject has uncontrolled diabetes or hypertension
• Clinical significant bleeding diathesis or coagulopathy
• Thrombotic or embolic cerebrovascular accident

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

BMS-844203 (CT-322)

Experimental group

Treatment:

Drug: BMS-844203 (CT-322)